Massimiliano Camilli

Oct 22, 2024 | onlinelibrary.wiley.com | Massimiliano Camilli

Letter to the Editor Is it possible to establish a threshold to define the inflammatory risk of acute heart failure patients? Letter regarding the article ‘Burst steroid therapy for acute heart failure: the CORTAHF randomized, open-label, pilot trial’ First published: 22 October 2024 No abstract is available for this article. References 1Cotter G, Davison BA, Freund Y, Voors AA, Edwards C, Novosadova M, et al.

Jul 4, 2024 | onlinelibrary.wiley.com | Massimiliano Camilli |Valentina Rossi |Antonio Cannata |Federico Ballacci

Introduction Iron deficiency (ID) is common in patients with cardiovascular diseases.1 It is associated with higher mortality and recurrent hospitalizations in patients with heart failure (HF), independently of haemoglobin levels.1 Notably, compared to placebo, supplementation with intravenous iron has been demonstrated to reduce the risk of HF hospitalization and mortality in numerous randomized clinical trials,2-7 leading to the introduction of ferric compounds in published HF...

Jul 1, 2024 | jacc.org | Massimiliano Camilli |Carlo Maria Cipolla |Susan Dent |Giorgio Minotti

Introduction Since the 1980s, anthracyclines, including doxorubicin, daunorubicin, epirubicin, and idarubicin, have been central to treating various hematologic and solid malignancies, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (nHL), acute leukemias, breast cancer (BC), ovarian cancer, and sarcomas.1,2 In clinical practice, the application of anthracyclines is limited by a dose-dependent cardiotoxicity, leading to both systolic and diastolic cardiac dysfunction and, in less common...

Oct 9, 2023 | jpet.aspetjournals.org | Giorgio Minotti |Massimiliano Camilli

High plasma levels of low-density lipoprotein cholesterol (LDL-C) have long been known to associate with a measurable increase of cardiovascular (CV) events in the general population. LDL-C lowering drugs, from the venerable statins to ezetimibe and PCSK9 inhibitors, are therefore pillars of the clinical management of patients with high LDL-C, but the magnitude of reduction of CV events in the at-risk patients remains a matter of controversy.

Apr 20, 2023 | futuremedicine.com | Andrea Tedeschi |Massimiliano Camilli |Enrico Ammirati |Piero Gentile

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.